Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials
Young-Mo Yang, Eun Joo Choi Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, South Korea Background: With the appearance of oral direct-acting antivirals (DAAs), the field of hepatitis C virus (HCV) treatment has been dramatically changed. This evolution makes possible for al...
Saved in:
Main Authors: | Yang YM (Author), Choi EJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
by: Mir F, et al.
Published: (2017) -
Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis
by: Hussien Ahmed, et al.
Published: (2018) -
Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
by: Carlo Smirne, et al.
Published: (2021) -
Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin
by: Mohamed DA Abd Alla, et al.
Published: (2018) -
O13 Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study
by: J. Grebely, et al.
Published: (2017)